Oral Edaravone – Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis

References

• Brown RH, Al-Chalabi A, Longo DL. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162–172. doi: 10.1056/NEJMra1603471
   PubMed Web of Science ®Google Scholar
• Brooks BR, Jorgenson JA, Newhouse BJ, et al. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion. Am J Manag Care. 2018;24(suppl 9):S175–S186.
   PubMed Web of Science ®Google Scholar
• Richards D, Morren JA, Pioro EP. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J Neurol Sci. 2020;417:117054. doi: 10.1016/j.jns.2020.117054
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227–1233. doi: 10.1212/WNL.0b013e3181bc01a4
   PubMed Web of Science ®Google Scholar
• Rilutek® (riluzole). Prescribing information. Cary NC: Covis Pharmaceuticals, Inc.; 2016 Apr.
   Google Scholar
• Radicava® (edaravone) injection and Radicava ORS® (edaravone) oral suspension. Prescribing information. Jersey City NJ: Mitsubishi Tanabe Pharma Corporation; 2022 May.
   Google Scholar
• Relyvrio™ (sodium phenylbutyrate and taurursodiol). Prescribing information. Cambridge MA: Amylyx Pharmaceuticals Inc.; 2022 Sep.
   Google Scholar
• QALSODY™ (tofersen) injection. Prescribing information. Cambridge MA: Biogen MA Inc.; 2023 Apr.
   Google Scholar
• Jami MS, Salehi-Najafabadi Z, Ahmadinejad F, et al. Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress. Neurochem Int. 2015;90:134–141. doi: 10.1016/j.neuint.2015.07.024
   PubMed Web of Science ®Google Scholar
• Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta. 2006;1762(11–12):1051–1067. doi: 10.1016/j.bbadis.2006.03.008
   PubMed Web of Science ®Google Scholar
• Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505–512. doi: 10.1016/S1474-4422(17)30115-1
   PubMed Web of Science ®Google Scholar
• Genge A, Pattee GL, Sobue G, et al. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Muscle Nerve. 2023;67(2):124–129. doi: 10.1002/mus.27768
   PubMedGoogle Scholar
• Shimizu H, Nishimura Y, Shiide Y, et al. Bioequivalence study of oral suspension and intravenous formulation of edaravone in healthy adult subjects. Clin Pharmacol Drug Dev. 2021;10(10):1188–1197. doi: 10.1002/cpdd.952
   PubMed Web of Science ®Google Scholar
• Chio A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118–130. doi: 10.1159/000351153
   PubMed Web of Science ®Google Scholar
• Mehta P, Raymond J, Punjani R, et al. Incidence of amyotrophic lateral sclerosis in the United States, 2014-2016. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(5–6):378–382. doi: 10.1080/21678421.2021.2023190
   PubMed Web of Science ®Google Scholar
• Manjaly ZR, Scott KM, Abhinav K, et al. The sex ratio in amyotrophic lateral sclerosis: a population based study. Amyotroph Lateral Scler. 2010;11(5):439–442. doi: 10.3109/17482961003610853
   PubMed Web of Science ®Google Scholar
• Kaye WE, Wagner L, Wu R, et al. Evaluating the completeness of the national ALS registry, United States. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(1–2):112–117. doi: 10.1080/21678421.2017.1384021
   PubMed Web of Science ®Google Scholar
• Weisskopf MG, O’Reilly EJ, McCullough ML, et al. Prospective study of military service and mortality from ALS. Neurology. 2005;64(1):32–37. doi: 10.1212/01.WNL.0000148649.17706.D9
   PubMed Web of Science ®Google Scholar
• Rowland LP. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol. 2001;58(3):512–515. doi: 10.1001/archneur.58.3.512
   PubMed Web of Science ®Google Scholar
• Wobst HJ, Mack KL, Brown DG, et al. The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future. Med Res Rev. 2020;40(4):1352–1384. doi: 10.1002/med.21661
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (Als)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(3):191–206. doi: 10.1080/14660820310002601
   PubMedGoogle Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994;330(9):585–591. doi: 10.1056/NEJM199403033300901
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet. 1996;347(9013):1425–1431. doi: 10.1016/S0140-6736(96)91680-3
   PubMed Web of Science ®Google Scholar
• Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919–930. doi: 10.1056/NEJMoa1916945
   PubMed Web of Science ®Google Scholar
• Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31–39. doi: 10.1002/mus.27091
   PubMed Web of Science ®Google Scholar
• Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099–1110. doi: 10.1056/NEJMoa2204705
   PubMed Web of Science ®Google Scholar
• Yoshino H. Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother. 2019;19(3):185–193. doi: 10.1080/14737175.2019.1581610
   PubMed Web of Science ®Google Scholar
• Ito H, Wate R, Zhang J, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213(2):448–455. doi: 10.1016/j.expneurol.2008.07.017
   PubMed Web of Science ®Google Scholar
• Aoki M, Warita H, Mizuno H, et al. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Res. 2011;1382:321–325. doi: 10.1016/j.brainres.2011.01.058
   PubMed Web of Science ®Google Scholar
• Soejima-Kusunoki A, Okada K, Saito R, et al. The protective effect of edaravone on TDP-43 plus oxidative stress-induced neurotoxicity in neuronal cells: analysis of its neuroprotective mechanisms using RNA sequencing. Pharmaceuticals (Basel). 2022;15(7):842. doi: 10.3390/ph15070842
   PubMedGoogle Scholar
• Shimizu H, Nishimura Y, Shiide Y, et al. Evaluation of pharmacokinetics, safety, and drug-drug interactions of an oral suspension of edaravone in healthy adults. Clin Pharmacol Drug Dev. 2021;10(10):1174–1187. doi: 10.1002/cpdd.925
   PubMed Web of Science ®Google Scholar
• Jackson C, Heiman-Patterson T, Kittrell P, et al. Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7–8):605–610. doi: 10.1080/21678421.2019.1645858
   PubMed Web of Science ®Google Scholar
• Shimizu H, Nishimura Y, Shiide Y, et al. Edaravone administered orally and via nasogastric tube in healthy adults: a comparative bioavailability phase 1 study. Clin Pharmacol Drug Dev. 2023;12(1):77–84. doi: 10.1002/cpdd.1175
   PubMed Web of Science ®Google Scholar
• Nakamaru Y, Kinoshita S, Kawaguchi A, et al. Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):80–87. doi: 10.1080/21678421.2017.1353100
   PubMedGoogle Scholar
• Lunetta C, Moglia C, Lizio A, et al. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020;267(11):3258–3267. doi: 10.1007/s00415-020-09993-z
   PubMed Web of Science ®Google Scholar
• Vu M, Tortorice K, Zacher J, et al. Assessment of use and safety of edaravone for amyotrophic lateral sclerosis in the veterans affairs health care system. JAMA Netw Open. 2020;3(10):e2014645. doi: 10.1001/jamanetworkopen.2020.14645
   PubMed Web of Science ®Google Scholar
• Witzel S, Maier A, Steinbach R, et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79(2):121–130. doi: 10.1001/jamaneurol.2021.4893
   PubMed Web of Science ®Google Scholar
• Ronquest NA, Paret K, Lucas A, et al. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022;14:499–511. doi: 10.2147/CEOR.S359025
   PubMed Web of Science ®Google Scholar
• Writing Group On Behalf Of The Edaravone (MCI-186) ALS 19 Study Group. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):55–63. doi: 10.1080/21678421.2017.1364269
   PubMedGoogle Scholar
• Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7–8):610–617. doi: 10.3109/21678421.2014.959024
   PubMed Web of Science ®Google Scholar
• Palumbo JM, Hubble J, Apple S, et al. Post-hoc analyses of the edaravone clinical trials study 16 and study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5–6):421–431. doi: 10.1080/21678421.2019.1599955
   PubMed Web of Science ®Google Scholar
• Maragakis NJ. What can we learn from the edaravone development program for ALS? Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):98–103. doi: 10.1080/21678421.2017.1361446
   PubMedGoogle Scholar
• Takei K, Watanabe K, Yuki S, et al. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):5–10. doi: 10.1080/21678421.2017.1353101
   PubMedGoogle Scholar
• Beydoun SR, Rosenfeld J. Edaravone in amyotrophic lateral sclerosis—lessons from the clinical development program and the importance of a strategic clinical trial design. US Neurol. 2018;14(1):47–53. doi: 10.17925/USN.2018.14.1.47
   Google Scholar
• Brooks BR, Berry JD, Ciepielewska M, et al. Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis. EClinicalMedicine. 2022;52:101590. doi: 10.1016/j.eclinm.2022.101590
   PubMedGoogle Scholar
• Brooks BR, Heiman-Patterson T, Wiedau-Pazos M, et al. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of study 19 (MCI186-19) [clinical trial NCT01492686]. PLoS One. 2022;17(6):e0258614. doi: 10.1371/journal.pone.0258614
   PubMed Web of Science ®Google Scholar
• Brooks BR, Pioro EP, Beaulieu D, et al. Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(1–2):49–57. doi: 10.1080/21678421.2021.1927102
   PubMed Web of Science ®Google Scholar
• Shefner J, Heiman-Patterson T, Pioro EP, et al. Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of study 19 (MCI186-19). Muscle Nerve. 2020;61(2):218–221. doi: 10.1002/mus.26740
   PubMed Web of Science ®Google Scholar
• Castrillo-Viguera C, Grasso DL, Simpson E, et al. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11(1–2):178–180. doi: 10.3109/17482960903093710
   PubMed Web of Science ®Google Scholar
• Aurilio G, Gori S, Nole F, et al. Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology. Tumori. 2016;102(1):108–113. doi: 10.5301/tj.5000383
   PubMed Web of Science ®Google Scholar
• Ciruelos EM, Diaz MN, Isla MD, et al. Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer. Eur J Cancer Care (Engl). 2019;28(6):e13164. doi: 10.1111/ecc.13164
   PubMed Web of Science ®Google Scholar
• Geba D, Mohd Sani J, Gascon M, et al. Hereditary angioedema patients would prefer newer-generation oral prophylaxis. J Drug Assess. 2021;10(1):51–56. doi: 10.1080/21556660.2020.1863699
   PubMed Web of Science ®Google Scholar
• Safety extension study of oral edaravone administered in subjects with amyotrophic lateral sclerosis (ALS). ClinicalTrials.Gov identifier: NCT04577404. Updated May 13, 2022. Accessed May 13, 2022. https://clinicaltrials.gov/ct2/show/NCT04577404
   Google Scholar
• Genge A, Brooks BR, Oskarsson B, et al. Analysis of the US safety data for edaravone (Radicava®) from the third year after launch. Drugs R D. 2022;22(3):205–211. doi: 10.1007/s40268-022-00391-6
   PubMed Web of Science ®Google Scholar
• Hirai M, Ishizaki K, Matsuda H, et al. Surveillance of using novel free radical scavenger, edaravone to investigate survival effect for ALS patients in Japan (SUNRISE Japan): a study design. J Neurol Sci. 2017;381:381. doi: 10.1016/j.jns.2017.08.592
   Web of Science ®Google Scholar
• Ishizaki K, Yoshimura K, Yoshida K, et al. Real-world safety of the novel, free radical scavenger edaravone for amyotrophic lateral sclerosis patients: data from the post-marketing surveillance SUNRISE Japan. Neurol Clin Neurosci. 2021;9(3):223–229. doi: 10.1111/ncn3.12490
   Web of Science ®Google Scholar
• Rothstein JD. Edaravone: a new drug approved for ALS [Editorial: bench to bedside]. Cell. 2017;171(4):725. doi: 10.1016/j.cell.2017.10.011
   PubMed Web of Science ®Google Scholar
• Xu X, Shen D, Gao Y, et al. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed? Transl Neurodegener. 2021;10(1):29. doi: 10.1186/s40035-021-00250-5
   PubMed Web of Science ®Google Scholar
• Taylor JP, Brown RH Jr., Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197–206. doi: 10.1038/nature20413
   PubMed Web of Science ®Google Scholar
• Radicava® (edaravone) findings in biomarkers from ALS (REFINE-ALS). ClinicalTrials.Gov identifier: NCT04259255. Updated Aug 8, 2022. Accessed Aug 8, 2022. https://clinicaltrials.gov/ct2/show/NCT04259255
   Google Scholar
• Center for innovation and bioinformatics (CIB) ALS/MND natural history consortium. Accessed Jan 24, 2023. https://www.data4cures.org/natural-history-consortium
   Google Scholar
• Soares P, Silva C, Chavarria D, et al. Drug discovery and amyotrophic lateral sclerosis: emerging challenges and therapeutic opportunities. Ageing Res Rev. 2022;83:101790. doi: 10.1016/j.arr.2022.101790
   PubMed Web of Science ®Google Scholar